Community Research and Development Information Service - CORDIS


A new murine cell line, named MG1361, was established from mammary adenocarcinomas arising in a MMTV-neu transgenic mouse lineage where breast tumours develop in 100% of females, due to the over-expression of the activated rat neu oncogene in the mammary gland. The MG1361 cell line shows an epithelial-like morphology, has poor plating efficiency, low clonogenic capacity, and a doubling time of 23.8 hours. Karyotype and flow cytometry analysis revealed a hypotetraploid number of chromosomes, whereas cell cycle analysis showed 31.2% of cells to be in the G1 phase, 21.4% in S and 47.4% in G2+M. This cell line maintains a high level of neu expression in vitro. He MG1361 cell line was tumorigenic when inoculated in immunodeficient (nude) mice and the derived tumors show the same histological features as the primary tumors from which they were isolated. MG1361 cells were positive for specific ER and PgR binding which was competed by tamoxifen, making this cell line useful for the evaluation of endocrine therapy. Moreover, they were sensitive to etoposide treatment, suggesting that they could be a model for the study of chemotherapy-induced apoptosis. As the tumors arising in MMTV-neu transgenic mice have many features in common with human mammary adenocarcinomas, this cell line can be utilized to perform basic studies on the role of the neu oncogene in the maintenanceof the transformed phenotype, an to test novel protocols of therapeutic strategies.

Additional information

Authors: SACCO M G, CNR Milano (IT);ZUCCHI I, IHCP, MVMC Unit, Geel (BE);BAGNASCO L, IHCP, MVMC Unit, Geel (BE);VEZZONI P, IHCP, MVMC Unit, Geel (BE);VILLA A, IHCP, MVMC Unit, Geel (BE);GRIBALDO L, University of Genova (IT);COLLOTTA A, University of Genova (IT);BARBIERI O, University of Pisa (IT);TURCHI G, Istituto Ricerche Biomediche, Torino (IT);BARONE D, Environment Institute, ispra (IT);MARAFANTE E,
Bibliographic Reference: Article: Breast cancer research and treatment, 47 (1998) 171-180
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top